Dr Reddys Laboratories Ltd's Q1FY26 Quarter Results
- 24 Jul 2025
Result Summary
- Dr Reddys Laboratories Ltd reported a 21.2% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Jun (Q1FY26). On a year-on-year (YoY) basis, it witnessed a growth of 12.4%.
- Its expenses for the quarter were up by 21.5% QoQ and 15.8% YoY.
- The net profit increased 7.6% QoQ and increased 1.3% YoY.
- The earnings per share (EPS) of Dr Reddys Laboratories Ltd stood at 17 during Q1FY26.
Financial Statments for Q1FY26
| (₹ crores) | Q1FY26 | Q4FY25 | Q1FY25 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 8862.40 | 7311.30 | 7883.30 | 21.2% | 12.4% |
Total Expenses | 6957.60 | 5726.90 | 6006.60 | 21.5% | 15.8% |
Profit Before Tax | 1904.80 | 1601.70 | 1876.70 | 18.9% | 1.5% |
Tax | 495.10 | 295.40 | 490.20 | 67.6% | 1.0% |
Profit After Tax | 1409.90 | 1309.80 | 1392.40 | 7.6% | 1.3% |
Earnings Per Share | 17.00 | 78.50 | 83.50 | -78.3% | -79.6% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Dr Reddy's Laboratories Ltd is a prominent pharmaceutical company headquartered in India. The company is known for its expertise in producing generic medications, active pharmaceutical ingredients (APIs), and proprietary products. Operating in the highly competitive pharmaceutical industry, Dr Reddy's Laboratories is committed to providing affordable and innovative healthcare solutions. The company offers a diverse range of products, including over-the-counter drugs, biosimilars, and custom pharmaceutical services. While specific recent developments are not available, Dr Reddy's Laboratories is known for its strategic focus on expanding its product portfolio and enhancing its global presence through collaborations and acquisitions.
Revenue
In the first quarter of the fiscal year 2026 (Q1FY26), Dr Reddy's Laboratories Ltd reported a total income of ₹8862.40 crores. This represents a significant quarter-over-quarter (QoQ) increase of 21.2% compared to the ₹7311.30 crores recorded in the fourth quarter of fiscal year 2025 (Q4FY25). Year-over-year (YoY), the total income grew by 12.4% from ₹7883.30 crores in the first quarter of fiscal year 2025 (Q1FY25). This growth in revenue highlights a positive trend in the company's ability to increase its income over both the quarter and the year.
Profitability
The profitability metrics for Dr Reddy's Laboratories Ltd show a solid performance in Q1FY26. The company reported a profit before tax (PBT) of ₹1904.80 crores, showing an 18.9% QoQ increase from ₹1601.70 crores in Q4FY25. On a YoY basis, the PBT saw a modest increase of 1.5% from ₹1876.70 crores in Q1FY25. After accounting for taxes, the profit after tax (PAT) for Q1FY26 was ₹1409.90 crores, reflecting a 7.6% increase QoQ from ₹1309.80 crores in Q4FY25 and a slight YoY rise of 1.3% from ₹1392.40 crores in Q1FY25. The earnings per share (EPS) in Q1FY26 was ₹17.00, indicating a significant decrease of 78.3% QoQ from ₹78.50 in Q4FY25 and a YoY decline of 79.6% from ₹83.50 in Q1FY25.
Operating Metrics
The operating metrics for Dr Reddy's Laboratories Ltd in Q1FY26 reveal a total expense of ₹6957.60 crores, which represents a 21.5% increase QoQ from ₹5726.90 crores in Q4FY25. On a YoY basis, the total expenses rose by 15.8% from ₹6006.60 crores in Q1FY25. The tax expense for Q1FY26 was ₹495.10 crores, showing a substantial QoQ increase of 67.6% from ₹295.40 crores in Q4FY25 and a slight YoY increase of 1.0% from ₹490.20 crores in Q1FY25. These operating metrics provide insight into the company's cost structure and tax obligations during the period under review.